It is all change at Sandoz this year, as Novartis has executed a 180-degree strategy shift. No longer is it pursuing its previous policy of ever closer union with the innovative pharma division, but instead it now favours far greater autonomy for its generic...
Happy returns? Hikma’s R&D formula poses some challenges
At the Hikma investor day at the end of last year, CEO Siggi Olafsson made in interesting observation on the company’s R&D productivity. Noting that Hikma was putting 7% of its turnover into R&D but that the sales from newly-launched products in H1 2018...